MedTrace Logo

Safety of Larazotide Acetate in Healthy Volunteers

NCT00386490 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2017-09-12

No results posted yet for this study

Summary

To demonstrate the safety, tolerance and pharmacokinetics of multiple, oral doses of larazotide acetate.

Conditions

  • Healthy

Interventions

DRUG

larazotide acetate

capsule for oral administration

Sponsors & Collaborators

  • 9 Meters Biopharma, Inc.

    lead INDUSTRY

Principal Investigators

  • Blake Paterson, MD · Alba Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-01-10
Primary Completion
2006-02-27
Completion
2006-02-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00386490 on ClinicalTrials.gov